Name: XL092
Brand: Selleck Chemicals
SKU: E0142
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: Purity: 99.78%

99.78

Related Targets	EGFR VEGFR FGFR PDGFR Src MEK CSF-1R FLT3 HER2 c-Kit
Other c-Met Inhibitors	Tepotinib (EMD-1214063) Dihexa SGX-523 PHA-665752 Foretinib (GSK1363089, XL880) SU11274 BMS-777607 JNJ-38877605 Tivantinib PF-04217903

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (189.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.710mg/ml (1.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 14.2 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.710mg/ml (1.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 14.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	528.53	Formula	C₂₉H₂₅FN₄O₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2367004-54-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	JUN04542			SMILES	CNC(=O)C1=CC2=C(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3)C=CN=C2C=C1OC

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	VEGFR2 (in cell-based assay) 1.6 nM AXL (in cell-based assay) 3.4 nM MER (in cell-based assay) 7.2 nM MET (in cell-based assay) 15 nM
References	[1] https://www.ejcancer.com/article/S0959-8049(20)31107-2/fulltext

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-26)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06959641	RECRUITING	Locally Advanced Differentiated Thyroid Gland Carcinoma; Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma; Locally Advanced Thyroid Gland Follicular Carcinoma; Locally Advanced Thyroid Gland Oncocytic Carcinoma; Locally Advanced Thyroid Gland Papillary Carcinoma; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Poorly Differentiated Thyroid Gland Carcinoma; Metastatic Thyroid Gland Follicular Carcinoma; Metastatic Thyroid Gland Oncocytic Carcinoma; Metastatic Thyroid Gland Papillary Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Refractory Poorly Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Follicular Carcinoma; Refractory Thyroid Gland Oncocytic Carcinoma; Refractory Thyroid Gland Papillary Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Thyroid Gland Follicular Carcinoma AJCC v8; Stage III Thyroid Gland Papillary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Thyroid Gland Follicular Carcinoma AJCC v8; Stage IV Thyroid Gland Papillary Carcinoma AJCC v8	Jochen Lorch	2025-06-06	PHASE2
NCT06082167	ACTIVE_NOT_RECRUITING	Head and Neck Squamous Cell Carcinoma	Exelixis	2024-06-07	PHASE2; PHASE3
NCT07773454	NOT_YET_RECRUITING	Cancer; Pediatric Cancer	Exelixis	2026-09-30	PHASE1
NCT06571734	RECRUITING	Metastatic Leiomyosarcoma; Unresectable Leiomyosarcoma; Bone Sarcoma; Translocation-associated Soft Tissue Sarcoma; Synovial Sarcomas; Osteosarcoma Metastatic; Ewing Sarcoma; Ewing Sarcoma Metastatic; Sarcoma Metastatic; Sarcoma of Bone	Northwestern University	2024-09-19	PHASE2
NCT07578025	NOT_YET_RECRUITING	Metastatic Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8	City of Hope Medical Center	2026-11-28	PHASE2
NCT06794229	RECRUITING	Locally Advanced Renal Cell Carcinoma	Qian Qin	2025-10-30	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

XL092 c-Met inhibitor

Chemical Structure

Molecular Weight: 528.53